IndustryCompany release

Protalix reaffirms 2026 revenue guidance as Elfabrio wins Brazil approval for both dosing regimens

🇺🇸 Protalix BioTherapeutics, Inc. (PLX) · Tue 10 Nov 2026

Protalix BioTherapeutics reported nine-month revenue of $75.6M and net income of $26.1M, while enrolment continues in its Phase 2 PRX-115 gout study.

Protalix BioTherapeutics reported its third-quarter 2026 results on 10 November, with revenue for the first nine months of the year at $75.6M and net income of $26.1M. The company said it expects to meet or exceed its full-year revenue guidance of $78M to $83M.

On the regulatory side, Elfabrio, the Fabry disease therapy Protalix partners with Chiesi, has received marketing authorization in Brazil. The approval covers both the every-two-weeks and every-four-weeks dosing regimens.

In its pipeline, Protalix said enrolment is continuing in RELEASE, a Phase 2 study of PRX-115 in uncontrolled gout. Top-line data are expected in the second half of 2027.

The material available for this report was limited to the company's headline results and summary. Details such as the quarterly breakdown, the Brazilian approval date and the study design were not available.

What it means for your team

  • Brazilian approval of both Elfabrio regimens gives Fabry disease prescribers and payers there two dosing schedules to consider, which may be relevant to market-access planning.
  • Teams tracking gout therapies should note that PRX-115 Phase 2 data are not expected until the second half of 2027.
  • The Chiesi partnership remains central to Elfabrio's commercial reach, so regional launch and reimbursement activity is likely to be led through that relationship.

Company's press release (SEC filing): Protalix BioTherapeutics, Inc. ↗

Article written by VigiEye from the official source (Protalix BioTherapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →